{"id":"tp-41943","type":"article-newspaper","title":"Pfizer’s Elrexfio Meets Phase 3 Endpoint in Earlier-Line Myeloma Study","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/41943","datePublished":"2026-10-27T18:46:09.000Z","dateModified":"2026-10-27T18:46:09.000Z","language":"en","abstract":"The trial enrolled 523 adults across 26 countries. Elrexfio’s current U.S. indication covers patients who have received at least four prior lines of therapy.","section":"Business","references":[]}